Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 8;14(3):2961–2969. doi: 10.3892/ol.2017.6555

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Effect of PI-PLC pre-treatment on trastuzumab-induced CDC in SK-BR-3 and BT474 cells. (A) Lysis rates in SK-BR-3 and BT474 cells following pre-treatment with PI-PLC (0.01, 0.05, 0.1 and 0.2 U/ml) cells for 1 h at 37°C followed by incubation with 50 µg/ml trastuzumab + 50% NHS. *P<0.05, compared with the control (0 U/ml). (B) Representative flow cytometry histograms (white, control of similar type; gray, pre-treatment; black, post-treatment) and (C) quantification of CD55 and CD59 expression in SK-BR-3 and BT474 cells following 0.1 U/ml PI-PLC treatment. *P<0.05, compared with before PI-PLC treatment. CDC, complement-dependent cytotoxicity; CD55, complement decay-accelerating factor; CD59, CD59 glycoprotein precursor; PI-PLC, phosphatidylinositol-specific phospholipase C.